CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- 4 Shares withheld for taxes Chief Financial Officer gave up 11,908 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Executive Officer gave up 36,197 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 26,571 shares (to pay taxes)
- 4 Grant or award Director acquired 2,268 shares (grant or award)
- 4 Grant or award Director acquired 2,745 shares (grant or award)
- 4 Planned sale Chief Executive Officer sold 138,574 shares at $6.04 ($836,987)
- 4 Shares withheld for taxes Chief Financial Officer gave up 7,057 shares (to pay taxes)
- 4 Grant or award Director acquired 36,549 shares (grant or award)
- 4 Grant or award Director acquired 36,549 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Chief Executive Officer sold 40,000 shares at an average $6.48 ($259,000)
- 4 Shares withheld for taxes Chief Executive Officer gave up 17,132 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Financial Officer gave up 10,879 shares (to pay taxes)
- 4 Planned sale Chief Executive Officer sold 40,000 shares at an average $7.90 ($316,000)
- 4 Shares withheld for taxes Chief Financial Officer gave up 6,544 shares (to pay taxes)
- 4 Shares withheld for taxes Chief R&D Commercial Officer gave up 2,753 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Executive Officer gave up 5,569 shares (to pay taxes)
- 4 Planned sale Chief Executive Officer sold 40,000 shares at an average $7.18 ($287,200)
- 4 Grant or award Director acquired 1,907 shares (grant or award)
Page 6 of 26 · 512 filings